ARS Pharmaceuticals, Inc. (SPRY) Earnings Call Transcripts

ARS Pharmaceuticals, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, ARS Pharmaceuticals reported total revenue of $22.7 million, driven by $17.5 million in U.S. net product revenue for neffy, which reflects a year-over-year growth of 3x in prescription volume and over double the revenue. Management highlighted ongoing efforts to improve access and affordability for neffy, with a significant focus on reducing prior authorization barriers and expanding commercial coverage, particularly through CVS Caremark. The company anticipates continued growth in the second half of 2026, supported by new initiatives and an expanded sales force, although operational challenges remain in the Medicaid segment and prior authorization processes.

Reported metrics

Guidance from management

Management expects revenue growth to be weighted towards the second half of 2026 as prescribing patterns evolve and refill dynamics begin to contribute. They indicated, "We would expect more consistent prescription capture and improved revenue through the second half of the year."

What management said

Thank you, Kathy. It's been a strong start to 2026, and we're underway on multiple work streams to continue to build and grow our neffy business. We expect neffy prescription growth to expand with the new initiatives we discussed that reduce provider and patient friction and which support current analyst consensus. A favorable CVS Caremark decision would only further accelerate our trajectory. I'm encouraged by the p...

Sure. As Rich mentioned and in my comments as well, we are nearing the process here of the approval process with CVS Caremark. When we look at what they represent in terms of the number of covered lives, CVS is 15%, Anthem is 5% and Aetna is 4%. So we do feel confident on the conversations that we've had with them. And as Rich said, the updated proposal that we provided back in April, this would align nicely with k...

What analysts pressed on

Analysts expressed concerns regarding the ongoing challenges with prior authorization processes and the potential impact on prescription volumes. There were questions about the timeline for CVS Caremark's approval and how it would affect access and sales growth in the near term.

Main topics on the call

• Strong Revenue Growth — ARS Pharmaceuticals generated $22.7 million in total revenue for Q1 2026, with U.S. net product revenue for neffy at $17.5 million, representing a 3x increase in prescription volume year-over-year. Management stated, "Ou...
• Improved Access Initiatives — Management reported achieving approximately 90% commercial coverage for neffy, with 57% of that coverage without prior authorization. The CEO noted, "This brings us to a total of 9 states covering neffy under Medicaid," ...
• Challenges with Prior Authorization — Management acknowledged that prior authorization remains a significant barrier to prescriber adoption, stating, "The primary barriers influencing prescriber adoption in this category are the prior authorization process a...
• New Pricing Strategy — A new initiative allows patients to purchase neffy at a maximum cash price of $199 at retail pharmacies, which was previously only available through specialty channels. This change aims to address high out-of-pocket cost...

Read the full ARS Pharmaceuticals, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 ARS Pharmaceuticals, Inc. earnings call transcripts on record, spanning August 12, 2024 to August 13, 2026. Based on this history, ARS Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SPRY

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

9

First call

August 12, 2024

Most recent

August 13, 2026

Reporting cadence

quarterly